Minrad expands revenue and loss

Minrad International's ability to sell sevoflurane in certain markets in 2007 more than doubled the Orchard Park, NY company's revenues in its most-recent quarter (end-June 30). Sevoflurane is a fluorinated methyl isopropyl ether used in general anesthesia.

Revenue increased to $4.304 million, compared with $2 million in the second quarter of 2006. The company also posted a net loss of $3.4 million, compared with a net loss of $1.7 million in the year-ago quarter.

Minrad attributed the greater loss to a decline in gross margin and added expenses in overhead, research and development, and administration, as well as additions to its sales force.

By AuntMinnie.com staff writers
August 16, 2007

Related Reading

Minrad nets CE Mark, September 11, 2006

Minrad names European, Latin America directors, July 20, 2006

Minrad revenues rise, April 18, 2006

Minrad promotes Bednarski, January 9, 2006

New line of credit for Minrad, December 22, 2005

Copyright © 2007 AuntMinnie.com

Page 1 of 3467
Next Page